AstraZeneca PLC Form 6-K Filing Summary
AstraZeneca PLC has announced positive results from its Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy for hypophosphatasia (HPP). The MULBERRY trial in treatment-naΓ―ve pediatric patients demonstrated statistically significant improvements in bone health. The CHESTNUT trial in pediatric patients switching from Strensiq showed a favorable safety profile and maintained therapeutic benefits. The HICKORY trial in adolescents and adults showed numerical improvements, with statistically significant benefits in specific subgroups and measures of fatigue and mobility. Efzimfotase alfa showed a generally well-tolerated safety profile across all trials. These results, which will be presented at a medical meeting and submitted to regulatory authorities, indicate efzimfotase alfa's potential to address unmet needs in the HPP patient population, offering a less frequent dosing option compared to Strensiq.